Brind.

Tariffs benefit AI stocks, while Bristol-Myers Squibb and Bain Capital launch an immunology spinout.

1 report, 1 independent Updated Sep 2

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Bristol-Myers Squibb Bain Capital

How it developed

Newest first. Tap a step to see who reported it.

Jun 26Bristol-Myers Squibb and Bain Capital announced large deals regarding drug programs, including co-founding an acquired company, Aiolos Bio.Sub-event
Sep 2AI stocks benefit from tariffs alongside a new immunology spinout partnership.1 source
- Insider Monkey

Keep exploring

The entities involved

Bristol-Myers Squibb
American pharmaceutical company
- Bristol-Myers Squibb is developing innovative treatments and supporting Cyprus' national effort in haematology.Mon 13:45
- FDA gave tentative approval to Lupin for an alternative formulation of a Bristol-Myers Squibb drug, which Lupin plans to manufacture in Somerset.Mon 09:09
Bain Capital
American alternative investment firm specialized in private equity, venture capital and credit products
- Ardian and Bain Capital discussed exit strategies within the private markets sector.Sun 04:06
- Bain Capital co-chairman and Eric Schmidt are reported to be backers of Solari Capital.Fri 11:57

Coverage

Newest first; wire copies grouped

Sep 2Insider MonkeyBristol-Myers Squibb Company (BMY) Launches $300M Immunology Spinout with Bain Capital We recently compiled a list of the 10 High Growth Pharma Stocks That Are Profitable in 2025. Bristol-Myers Squib